share_log
Breakings ·  Dec 16, 2024 19:28

HANSOH PHARMA: The B7-H3 targeted antibody-drug conjugate HS-20093 has received priority medicine designation from the EMA.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment